US2018344678A1PendingUtilityA1

Use of n-acetylcysteine to treat cns disorders

60
Assignee: NEURONASAL LLCPriority: May 2, 2017Filed: May 1, 2018Published: Dec 6, 2018
Est. expiryMay 2, 2037(~10.8 yrs left)· nominal 20-yr term from priority
Inventors:Rajiv R. RatanSaravanan KaruppagounderThomas I. Bradshaw
A61K 31/198A61K 31/145A61P 25/18A61K 9/0043A61P 25/24A61K 31/05
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E 2 .

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a central nervous system condition comprising administering to a subject in need thereof a therapeutically-effective amount of a 5-lipoxygenase activating protein (FLAP) inhibitor. 
     
     
         2 . The method of  claim 1 , wherein the FLAP inhibitor is N-acetylcysteine or a pharmaceutically-acceptable salt thereof. 
     
     
         3 . The method of  claim 1 , wherein the FLAP inhibitor is an N-acetylcysteine prodrug or a pharmaceutically-acceptable salt thereof. 
     
     
         4 . The method of  claim 1 , wherein the FLAP inhibitor is N-acetylcysteine amide or a pharmaceutically-acceptable salt thereof. 
     
     
         5 . The method of  claim 1 , wherein the FLAP inhibitor is cystamine or a pharmaceutically-acceptable salt thereof. 
     
     
         6 . The method of  claim 1 , wherein the FLAP inhibitor is nordihydroguaiaretic acid or a pharmaceutically-acceptable salt thereof. 
     
     
         7 . The method of  claim 1 , wherein the administering is intranasal. 
     
     
         8 . The method of  claim 1 , wherein the central nervous system condition is a brain injury. 
     
     
         9 . The method of  claim 1 , wherein the brain injury is a stroke. 
     
     
         10 . The method of  claim 9 , wherein the stroke is intracerebral hemorrhagic stroke. 
     
     
         11 . The method of  claim 8 , wherein the brain injury is subarachnoid hemorrhage. 
     
     
         12 . The method of  claim 1 , wherein the central nervous system condition is a neuropsychiatric disorder. 
     
     
         13 . The method of  claim 12 , wherein the neuropsychiatric disorder is schizophrenia. 
     
     
         14 . The method of  claim 12 , wherein the neuropsychiatric disorder is bipolar disorder. 
     
     
         15 . The method of  claim 12 , wherein the neuropsychiatric disorder is depression. 
     
     
         16 . The method of  claim 1 , wherein the central nervous system condition is spinal cord injury. 
     
     
         17 . The method of  claim 1 , wherein the central nervous system condition is associated with oxidative stress. 
     
     
         18 . The method of  claim 1 , wherein the central nervous system condition is associated with endoplasmic reticulum stress. 
     
     
         19 . The method of  claim 1 , wherein the central nervous system condition is associated with excitotoxic stress. 
     
     
         20 . The method of  claim 1 , wherein the therapeutically-effective amount is about 1 mg/kg to about 10 mg/kg. 
     
     
         21 . The method of  claim 1 , wherein the subject is human.

Join the waitlist — get patent alerts

Track US2018344678A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.